The company, a spin-out of ETH Zurich and the Paul Scherrer Institute, Switzerland, uses high throughput biochemical screening of compounds integrated into an artificial intelligence and cell pathways mathematical modeling process. This platform unlocks previously intractable targets, shortens timelines for drug discovery from years to months and reduces risks. The company focuses on the generation and optimization of drugs which trigger a specific and well characterized effect on signaling pathways, thus leading to higher therapeutic efficacy and reduced risk of toxicity. The company is specialized in GPCR drug discovery and covers hit-generation, hit- to-lead and lead optimization for all targets including orphan GPCRs. InterAx AG has a highly experienced and dedicated team of scientists specialized in AI, mathematical models of signaling pathways, cellular pharmacology and computational chemistry.
Company Details
- Employees
- 14
- Founded
- -
- Address
- Zürcherstrasse 39d, Schlieren,zurich 8952,switzerland
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- interaxbiotech.com
- HQ
- Schlieren, Zurich
Interax Biotech Questions
Interax Biotech's website is interaxbiotech.com
Interax Biotech's LinkedIn profile is https://ch.linkedin.com/company/interax-biotech
Interax Biotech has
14 employees.
View email and phone details for 14
employees at Interax Biotech.
Interax Biotech's industry is
Biotechnology Research
Interax Biotech's top competitors are
Aimorphous Health,
Clexbio,
Nxi Therapeutics Ag,
Scailyte,
Enantios,
Leadxpro Ag,
Trilliome,
Gio Therapeutics,
Araris Biotech Ag,
Immitra Bio Gmbh.
Interax Biotech's categories are Biotechnology Research
Interax Biotech's founding year is 2016
